Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Barata

Showing results (141-150 of 203) with videos related to

Pageof 21
Sort By:
Cancer Treatment and Research Communications|July 24, 2020
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancerMarcus Moses, Alex Niu, Michael B Lilly, et al.
European Urology|December 5, 2024
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary CancersPedro C Barata, Kevin K Zarrabi, Axel Bex, et al.
Clinical Genitourinary Cancer|September 3, 2018
Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell CarcinomaPedro C Barata, Prateek Mendiratta, Rupesh Kotecha, et al.
The Oncologist|October 7, 2025
Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancerRana R McKay, Shayan S Nazari, Andrew Elliott, et al.
Cancers|December 23, 2023
The Genomic Landscape of Urothelial Carcinoma with High and Low <i>ERBB2</i> ExpressionAgreen Hadadi, Harris B Krause, Andrew Elliott, et al.
Translational Andrology and Urology|May 21, 2026
Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinomaAlbert Jang, Sulin Wu, Hamsa L S Kumar, et al.
Cancers|April 26, 2025
The Influence of the Germline <i>HSD3B1</i> Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate CancerSamuel Kellen, Allison Makovec, Carly D Miller, et al.
Targeted Oncology|April 7, 2018
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent TherapiesPedro C Barata, Dhrmesh Gopalakrishnan, Vadim S Koshkin, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Cancer|August 11, 2023
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkersBassel Nazha, Tony Zhuang, Sharon Wu, et al.
Pageof 21

Showing results (141-150 of 203) with videos related to

Sort By:
Pageof 21
Cancer Treatment and Research Communications|July 24, 2020
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancerMarcus Moses, Alex Niu, Michael B Lilly, et al.
European Urology|December 5, 2024
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary CancersPedro C Barata, Kevin K Zarrabi, Axel Bex, et al.
Clinical Genitourinary Cancer|September 3, 2018
Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell CarcinomaPedro C Barata, Prateek Mendiratta, Rupesh Kotecha, et al.
The Oncologist|October 7, 2025
Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancerRana R McKay, Shayan S Nazari, Andrew Elliott, et al.
Cancers|December 23, 2023
The Genomic Landscape of Urothelial Carcinoma with High and Low <i>ERBB2</i> ExpressionAgreen Hadadi, Harris B Krause, Andrew Elliott, et al.
Translational Andrology and Urology|May 21, 2026
Variant allele frequency as a potential marker in response to frontline systemic therapy for patients with locally advanced and metastatic urothelial carcinomaAlbert Jang, Sulin Wu, Hamsa L S Kumar, et al.
Cancers|April 26, 2025
The Influence of the Germline <i>HSD3B1</i> Adrenal-Permissive Allele (c.1100 C) on the Somatic Alteration Landscape, the Transcriptome, and Immune Cell Infiltration in Prostate CancerSamuel Kellen, Allison Makovec, Carly D Miller, et al.
Targeted Oncology|April 7, 2018
Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent TherapiesPedro C Barata, Dhrmesh Gopalakrishnan, Vadim S Koshkin, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
Cancer|August 11, 2023
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkersBassel Nazha, Tony Zhuang, Sharon Wu, et al.
Pageof 21